Pyrazolo[4,3-d]pyrimidine Derivatives as a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Domain Inhibitor for the Treatment of Anemia

被引：10

作者：

Goi, Takashi ^{[1
,2
]}

Nakajima, Tatsuo ^{[1
]}

Komatsu, Yoshiyuki ^{[1
]}

Kawata, Atsushi ^{[1
]}

Yamakoshi, Shuhei ^{[1
]}

Okada, Okimasa ^{[1
]}

Sugahara, Masakatsu ^{[1
]}

Umeda, Asami ^{[1
]}

Takada, Yoko ^{[1
]}

Murakami, Jun ^{[1
]}

Ohashi, Rikiya ^{[1
]}

Watanabe, Tomoko ^{[1
]}

Fukase, Koichi ^{[2
]}

机构：

[1] Mitsubishi Tanabe Pharma Corp, Sohyaku Innovat Res Div, Yokohama, Kanagawa 2270033, Japan

[2] Osaka Univ, Dept Chem, Grad Sch Sci, Toyonaka, Osaka 5600043, Japan

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 07期

关键词：

renal anemia; hypoxia-inducible factor prolyl hydroxylase domain inhibitor; erythropoietin; pyrazolopyrimidine; solubility; KIDNEY; ERYTHROPOIETIN; DISCOVERY;

D O I：

10.1021/acsmedchemlett.0c00108

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibition of hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) promotes erythropoietin (EPO) production by stabilizing the HIF alpha subunit. Thieno[2,3-d]-pyrimidine 8 identified based on X-ray crystal structure analysis was optimized to lead to the discovery of pyrazolo[4,3-d]-pyrimidine 13 as the lead compound of orally bioavailable HIF-PHD inhibitors. Conversion of the benzyl moiety in 13 gave pyrazolopyrimidine 19 with high solubility and bioavailability, which increased hemoglobin levels in anemic model rats after repeated oral administration. It was shown that pyrazolo[4,3-d]pyrimidine derivatives are promising therapeutic agents for renal anemia through the inhibition of HIF-PHD.

引用

收藏

页码：1416 / 1420

页数：5

相关论文

共 50 条

[41] Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in Non-Dialysis Dependent Chronic Kidney Disease: Systematic Review and Meta-Analysis of Randomized Controlled Trials [J].

Tyagi, Jyoti ;

Kaur, Manveen ;

Moola, Sandeep ;

Ramachandran, Raja ;

Meena, Priti ;

Bajpai, Divya ;

Bhaumik, Soumyadeep .

INDIAN JOURNAL OF NEPHROLOGY, 2025, 35 (02) :217-233

[42] Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis [J].

Siliang Zhang ;

Jing Guo ;

Shuqin Xie ;

Jianwei Chen ;

Shenrun Yu ;

Yuan Yu .

International Urology and Nephrology, 2021, 53 :1139-1147

[43] Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis [J].

Zhang, Siliang ;

Guo, Jing ;

Xie, Shuqin ;

Chen, Jianwei ;

Yu, Shenrun ;

Yu, Yuan .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2021, 53 (06) :1139-1147

[44] Novel pyrazolo[4,3-d]pyrimidine microtubule targeting agents (MTAs): Synthesis, structure-activity relationship, in vitro and in vivo evaluation as antitumor agents [J].

Islam, Farhana ;

Quadery, Tasdique M. ;

Bai, Ruoli ;

Luckett-Chastain, Lerin R. ;

Hamel, Ernest ;

Ihnat, Michael A. ;

Gangjee, Aleem .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 41

[45] Safety and Efficacy of Hypoxia-Inducible Factor- Prolyl Hydroxylase Inhibitors vs. Erythropoietin- Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta- Analysis and Systematic Review [J].

Damarlapally, Nanush ;

Thimmappa, Vijaylaxmi ;

Irfan, Hamza ;

Sikandari, Muhammad ;

Madhu, Krupa ;

Desai, Aayushi ;

Pavani, Peddi ;

Zakir, Syeda ;

Gupta, Manvi ;

Khosa, Maha Mushtaq ;

Kotak, Sohny ;

Varrassi, Giustino ;

Khatri, Mahima ;

Kumar, Satesh .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)

[46] Pharmacological Characterization of 1-(5-Chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic Acid (JNJ-42041935), a Potent and Selective Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor [J].

Barrett, Terrance D. ;

Palomino, Heather L. ;

Brondstetter, Theresa I. ;

Kanelakis, Kimon C. ;

Wu, Xiaodong ;

Haug, Peter V. ;

Yan, Wen ;

Young, Andrew ;

Hua, Hong ;

Hart, Juliet C. ;

Da-Thao Tran ;

Venkatesan, Hariharan ;

Rosen, Mark D. ;

Peltier, Hillary M. ;

Sepassi, Kia ;

Rizzolio, Michele C. ;

Bembenek, Scott D. ;

Mirzadegan, Tara ;

Rabinowitz, Michael H. ;

Shankley, Nigel P. .

MOLECULAR PHARMACOLOGY, 2011, 79 (06) :910-920

[47] Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4-hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations [J].

Sayaf, Abrar Mohammad ;

Kousar, Kafila ;

Suleman, Muhammad ;

Albekairi, Norah A. ;

Alshammari, Abdulrahman ;

Mohammad, Anwar ;

Khan, Abbas ;

Agouni, Abdelali ;

Yeoh, Kar Kheng .

BMC CHEMISTRY, 2024, 18 (01)

[48] An expeditious four-component domino protocol for the synthesis of novel thiazolo[3,2-a] thiochromeno[4,3-d]pyrimidine derivatives as antibacterial and antibiofilm agents [J].

Suresh, Lingala ;

Kumar, P. Sagar Vijay ;

Poornachandra, Y. ;

Kumar, C. Ganesh ;

Babu, Nanubolu Jagadeesh ;

Chandramouli, G. V. P. .

BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (16) :3808-3817

[49] Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives [J].

Kandeel, Manal M. ;

Refaat, Hanan M. ;

Kassab, Asmaa E. ;

Shahin, Inas G. ;

Abdelghany, Tamer M. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2015, 90 :620-632

[50] Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors [J].

Zhang, Dajun ;

Yan, Yan ;

Jin, Ge ;

Liu, Bo ;

Ma, Xiaoliang ;

Han, Dan ;

Jia, Xiaojian .

ARCHIV DER PHARMAZIE, 2018, 351 (09)

← 1 2 3 4 5 →